🔍

Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies

Case ID:
C12570
Combined Therapeutic Method for Solid Tumor

JHU REF: [C12570]



Invention novelty: This technology is a combination therapy method including a tumor-specific bacterium and antibodies that boost tumor immune response.



Value Proposition

Worldwide cancer affects more than 12 million people each year. This number is expected to increase to 14 million each year by 2015.  Solid tumors generally contain hypoxic tumor cores where a few live tumor cells reside in a quiescent state. These core residing tumor cells are often resistant to standard treatments (e.g. radiotherapy and chemotherapy), survive initial treatment, and become a source for tumor recurrence and metastasis. This technology overcomes the challenge of destroying core residing tumor cells by combining the intravenous injection of a lytic tumor-specific bacterium with two antibodies that target immune cell surface receptors, eliciting a powerful anti-tumor response. Advantages of this technology include:
•    Enhanced efficacy for treating solid tumors compared to either antibody or lytic bacterium treatment alone
•    Reduced chance of cancer recurrence and increased patient survival and quality of life
•    Targeted therapy that specifically affects tumor cells, while healthy cells are unaffected



Technical Details

Johns Hopkins researchers have developed a combination therapeutic method for solid tumors. An attenuated anaerobic tumor core-targeting bacterial strain combined with anti-CTLA-4 and anti-PD-1 antibodies can effectively treat solid tumors. In a metastatic murine tumor model (4T1), the number of metastases was markedly reduced leading to significant survival benefit following a combination of tumor-lytic bacteria  (intravenously injected) and CTLA-4 and PD-1 antibodies (intraperitoneally injected). This method can be further developed into a therapeutic intervention for human patients with solid metastatic tumors.



Looking for Partners: To develop & commercialize the technology as a therapeutic method for solid tumors.



Stage of Development: Pre-clinical



Data Availability: Under CDA/NDA



Patent Status: Pending



Publication(s)/Associated Cases: Not at this time



Categories: Therapeutics

Keywords: solid tumor, cancer, anaerobic bacteria, anti-CTLA-4, anti-PD-1, combination therapy.
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies PCT: Patent Cooperation Treaty Australia 2015240884 2015240884 3/31/2015 10/1/2020 3/31/2035 Granted
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies PCT: Patent Cooperation Treaty Mexico MX/a/2016/012891 378397 3/31/2015 12/16/2020 3/31/2035 Granted
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies DIV: Divisional Japan 2020-58163 7001731 3/31/2015 12/28/2021 3/31/2035 Granted
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies DIV: Divisional Japan 2021-210353 7240685 3/31/2015 3/8/2023 3/31/2035 Granted
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies DIV: Divisional Australia 2020230294 2020230294 3/31/2015 6/8/2023 3/31/2035 Granted
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies DIV: Divisional Japan 2023-27184 7431409 3/31/2015 2/6/2024 3/31/2035 Granted
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies DIV: Divisional Australia 2023202788   3/31/2015     Pending
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies DIV: Divisional Japan 2024-008618   3/31/2015     Pending
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies PCT: Patent Cooperation Treaty Japan 2016-559826 6712952 3/31/2015 6/4/2020 3/31/2035 Granted
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies PCT: Patent Cooperation Treaty European Patent Office 15773992.1   3/31/2015     Pending
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies PCT: Patent Cooperation Treaty Canada 2,944,456 2,944,456 3/31/2015 10/31/2023 3/31/2035 Granted
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies PCT: Patent Cooperation Treaty United States 15/301,163   9/30/2016     Pending
Direct Link:
https://jhu.technologypublisher.com/technology/24286
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Jeanine Pennington
jpennin5@jhmi.edu
410-614-0300
Save This Technology:
Bookmark this page
JHTV Home | Search | Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum